ATHX, MGAM, OXBT - CRWESelect.com Stock News! Athersys, Multimedia Games Holding Company, Oxygen Biotherapeutics (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) February 1, 2012 -- To view video, and read the full article visit URL http://crweselect.com/28413/stock-alerts/athx-mgam-oxbt-crweselectcom-stock-news-athersys-multimedia-games-holding-company-oxygen-biotherapeutics-video-included-inside/

Athersys, Inc. (NASDAQ: ATHX)

Athersys, Inc. - Symbol ATHX - announced today grant funding aggregating $3.6 million to further advance its MultiStem(R) product programs and cell therapy platform. Specifically, Athersys was awarded a SBIR Fast-Track grant of up to $1.9 million from the National Institute of Neurological Disorders and Stroke (NINDS) to develop MultiStem for the treatment of traumatic brain injury (TBI). In addition, Athersys' subsidiary based in Belgium, ReGenesys BVBA, was awarded a $1.2 million (EURO0.9 million) grant from the Belgium's Agency for Innovation by Science and Technology (IWT) to further develop cell therapy formulations and manufacturing capabilities. The company has also been awarded funding recently to work in other areas, such as using MultiStem to treat chronic cardiovascular disease.

ATHX is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem(R) cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft versus host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products.

For more information about ATHX please visit http://www.athersys.com

****

Multimedia Games Holding Company, Inc. (NASDAQ: MGAM)

Multimedia Games Holding Company, Inc. - Symbol MGAM - fiscal 2012 first quarter revenue rose 21.6%, or $6.2 million, to $34.8 million, compared to revenue of $28.6 million in the fiscal 2011 first quarter. Fiscal 2012 first quarter revenue included approximately $24.9 million from gaming operations and approximately $9.6 million from gaming equipment and system sales, compared with $22.0 million in revenue from gaming operations and $6.1 million from gaming equipment and system sales in the year-ago period.

Through its wholly owned subsidiaries, MGAM develops and distributes gaming technology. The company is a creator and supplier of comprehensive systems, content and electronic gaming units for Native American gaming markets, as well as for commercial casinos and charity and international bingo markets. Revenue is primarily derived from gaming units in operation domestically and internationally installed on revenue-sharing arrangements. Multimedia Games also supplies the central determinant system for the video lottery terminals (“VLTs”) installed at racetracks in the State of New York. The company is focused on pursuing market expansion and new product development for Class II, Class III and VLT markets.

For more information about MGAM please visit http://www.multimediagames.com

****

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT)

Oxygen Biotherapeutics, Inc. - Symbol OXBT - and privately held Aurum Biosciences Ltd. of Glasgow, Scotland, today jointly announced they have signed a long-term agreement to develop a better tool for defining the extent of injury in acute ischemic stroke and for treating this emergency in the important early hours after the attack. At the center of both efforts is Oxygen Biotherapeutics' proprietary, perfluorocarbon-based Oxycyte emulsion, which is known for delivering large amounts of oxygen to the brain. The key to the diagnostic work lies in Aurum's proprietary GOLD (Glasgow Oxygen Level-Dependent) Magnetic Resonance Imaging (MRI) technology, which has already shown great promise in mapping potentially salvageable tissue in the brain after stroke in the brain.

Headquartered in Morrisville, NC, OXBT is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier product that is being formulated for both intravenous and topical delivery. Currently, Oxygen Biotherapeutics is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, personal care, and topical wound healing, and supports or collaborates with others researching the use of Oxycyte to treat other indications, including stroke. The company has commercialized its DERMACYTE(R) line of oxygen-rich skin care products.

For more information about OXBT please visit http://www.oxybiomed.com

To read the full article visit URL http://crweselect.com/28413/stock-alerts/athx-mgam-oxbt-crweselectcom-stock-news-athersys-multimedia-games-holding-company-oxygen-biotherapeutics-video-included-inside/

*****************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

ATHXcrweselect0201
MGAMcrweselect0201
OXBTcrweselect0201

Athersys     ATHX     Aurum Biosciences Ltd.     MGAM     Multimedia Games Holding Compa     MultiStem     oxbt     Oxygen Biotherapeutics